Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $382.7 million, a 3% increase year over year [7] - Adjusted EBITDAre was $73.6 million, up 7% year over year [7] - Normalized FFO increased 172% year over year to $18.6 million, or $0.08 per share [7] Business Line Data and Key Metrics Changes - Same property SHOP NOI increased by 18.5% year over year to $37.4 million [8] - Average monthly rate in the SHOP sector increased by 5.4% year over year, with occupancy rising by 160 basis points to 80.6% [8] - SHOP revenue increased by 6.2% year over year [8] - Medical office and life science portfolio had same property occupancy at 89.9%, down 10 basis points from Q1 [10] Market Data and Key Metrics Changes - The active leasing pipeline in the medical office and life science portfolio includes 691,000 square feet, with 246,000 square feet being new absorption [10] - Weighted average rents for new and renewal leasing activity were 11.5% higher than prior rents [10] Company Strategy and Development Direction - The company is focused on deleveraging its balance sheet through asset sales and refinancing at attractive rates [7] - DHC sold two unencumbered properties for a total of $16.4 million and three additional properties in July for $8.8 million [11] - The company aims to enhance its portfolio with a higher concentration of SHOP assets and stable cash flows from medical office and life science properties [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued recovery of the SHOP segment and the overall positive outlook for the business [10] - The company expects to meet its 2026 debt maturity and anticipates a reduction in leverage towards a target of 6.5 to 7.5 times [20] Other Important Information - The company reduced its 2025 CapEx guidance to $140 million to $160 million, a $10 million reduction from prior guidance [17] - As of July, the company had approximately $292 million in liquidity, including $142 million in unrestricted cash [18] Q&A Session Summary Question: Any notable one-time issues in Q2 2025? - Management indicated that the majority of the NOI benefit came in Q1, with a minor benefit in Q2 from PLGL insurance, approximately $1 million [24][38] Question: CapEx guidance change details? - The change was due to dispositions and a comparison of actual year-to-date spend against the budget [27] Question: Disposition pipeline and future sales? - Management confirmed a mix of assets under PSA and LOI, with additional properties expected to close by year-end or into 2026 [28][30] Question: Performance of Five Star assets compared to others? - Five Star properties have shown improvements due to operational enhancements and capital investments, leading to better performance [31][34] Question: Occupancy targets and growth expectations? - Management expects gradual occupancy growth towards the year-end target of over 82%, influenced by seasonal trends and ongoing dispositions [35]